With the success of immune checkpoint inhibitors for cancer therapy and considering the potent immune suppressive effects of TGF-β, it may be of particular interest to see whether TGF-β targeting agents can increase the efficiency and range of immune therapeutic agents. This evidence concerns the gene TGFB1 and cancer.